Basit öğe kaydını göster

dc.contributor.authorEroglu, Barbaros
dc.contributor.authorOzadali-Sari, Keriman
dc.contributor.authorUnsal-Tan, Oya
dc.contributor.authorDharmarajan, Sriram
dc.contributor.authorYogeeswari, Perumal
dc.contributor.authorBalkan, Ayla
dc.date.accessioned2019-12-16T10:09:15Z
dc.date.available2019-12-16T10:09:15Z
dc.date.issued2016
dc.identifier.issn1735-0328
dc.identifier.urihttps://doi.org/
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316256/
dc.identifier.urihttp://hdl.handle.net/11655/19877
dc.description.abstractTo develop novel antimycobacterial agents, a new series of thiazolidinone-azole hybrids 4a-b, 5a-b and 6-13 were designed and synthesized. Thiazolidin-4-ones (4a-b and 5a-b) were obtained by the reaction of Schiff bases and hydrazones (2a-b and 3a-b) with mercaptoacetic acid. 5-Benzylidene derivatives (6-13) were gained by treatment of 5a-b with appropriate benzaldehydes according to Knoevenagel condensation. To evaluate their structures 1H NMR, IR, mass spectrometry and elemental analysis data were used. The target compounds were screened for their antimycobacterial activity against M. tuberculosis H37Rv strain using the microplate alamar blue assay method. Among them, 6, 10 and 12 (MIC: 14.27-14.74 μM) were found as most active compounds in the series. It was seen that both phenylamino and benzylidene substitutions on thiazolidin-4-one ring caused an improvement in the antimycobacterial activity.
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleNovel Thiazolidinone-Azole Hybrids: Design, Synthesis And Antimycobacterial Activity Studies
dc.typeinfo:eu-repo/semantics/article
dc.relation.journalIranian Journal of Pharmaceutical Research : IJPR
dc.contributor.departmentFarmasötik Kimya
dc.identifier.volume15
dc.identifier.issue4
dc.identifier.startpage783
dc.identifier.endpage790
dc.description.indexPubMed


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster